CryoLife, Inc. Receives European And Canadian Approval To Market New Rigid Applicator Tip For BioGlue(R) Surgical Adhesive

ATLANTA, Dec. 13 /PRNewswire/ -- CryoLife, Inc., a biomaterials and biosurgical device company, today announced that it has received CE Mark and Health Canada approval for a new rigid applicator tip for its BioGlue Surgical Adhesive. The new tip, designed to reach areas beyond 27 cm, enables precise delivery of BioGlue over an extended length.

"With the increase in laparoscopic and video-assisted thoracoscopic surgeries, we've received many requests from our customers for a more rigid extension to our existing BioGlue applicator tips," said Steven G. Anderson, President and Chief Executive Officer, CryoLife, Inc. "The new rigid applicator tip, developed in response to those requests, enhances the physician's ability to control the delivery of BioGlue in minimally invasive surgeries, such as in partial nephrectomies, liver resections and hernia mesh fixations."

The new BioGlue Rigid Applicator Tip, 34 cm in length, is designed to be used with CryoLife's pre-loaded BioGlue cartridges.

First introduced to the European market in April 1998, BioGlue is accepted and used by surgeons worldwide as an integral part of their surgical practice. Clinically proven to provide immediate hemostasis, BioGlue is effective in bonding, sealing and reinforcing soft tissue in a broad range of indications.

About BioGlue

BioGlue is a two-component adhesive that creates a flexible, mechanical seal, independent of the body's clotting mechanism, within 20 to 30 seconds, and reaches its maximum bonding strength in two to three minutes.

The Company's BioGlue Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. In addition, BioGlue is CE-marked in the European Community and approved in Canada and Australia for use in soft tissue repair.

About CryoLife, Inc.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiovascular, vascular, and orthopaedic surgeries throughout the United States and Canada. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. The Company also distributes the CryoLife-O'Brien(R) stentless porcine heart valve and the SG Model 100 vascular graft, which are CE marked for distribution within the European Community.

Statements made in this press release that look forward in time or that express management's beliefs, expectations or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These future events may not occur as and when expected, if at all, and, together with the Company's business, are subject to various risks and uncertainties. These risks and uncertainties include that the new BioGlue syringe delivery device may not provide clinicians with improved convenience and ease of use to the extent anticipated or that even if it does, it may not spur increased use on the part of clinicians, that the Company's recently announced strategic directives may not generate anticipated revenue and earnings growth, the Company's efforts to continue to increase revenue may not be effective, since their effectiveness is subject to such factors as competitive pressures and tissue availability, that the Company's efforts to develop and introduce new products outside the U.S. may be unsuccessful, that the Company's efforts to improve procurement and tissue processing yields may not continue to prove effective, the possibility that the FDA could impose additional restrictions on the Company's operations, require a recall, or prevent the Company from processing and distributing tissues or manufacturing and distributing other products, that products and services under development, including BioDisc, may not be commercially feasible, the Company's SynerGraft products may not receive FDA approval when anticipated or at all, that the Company may not have sufficient borrowing or other capital availability to fund its business, that pending litigation cannot be settled on terms acceptable to the Company, that the Company may not have sufficient resources to pay punitive damages (which are not covered by insurance) or other liabilities in excess of available insurance, the possibility of decreases in the Company's working capital if cash flow does not improve, that to the extent the Company does not have sufficient resources to pay the claims against it, it may be forced to cease operations or seek protection under applicable bankruptcy laws, changes in laws and regulations applicable to CryoLife, efforts by existing stockholders or others to gain influence or control over CryoLife may divert management's attention from the Company's operational recovery or otherwise be detrimental to the interests of the other stockholders, existing or other potential litigation initiated by stockholders or others; possible litigation by CryoLife if stockholders or others make proposals or statements which CryoLife does not believe to be fair or accurate or in the best interests of its other shareholders and other risk factors detailed in CryoLife's Securities and Exchange Commission filings, including CryoLife's Form 10-K filing for the year ended December 31, 2005, its most recent Form 10-Q, and the Company's other SEC filings. The Company does not undertake to update its forward-looking statements.

For additional information about the company, visit CryoLife's Web site: http://www.cryolife.com. D. Ashley Lee Katie Brazel Executive Vice President, Fleishman Hillard Chief Financial Officer and Phone: 404-739-0150 Chief Operating Officer Phone: 770-419-3355

CONTACT: D. Ashley Lee, Executive Vice President, Chief Financial Officerand Chief Operating Officer, of CryoLife, Inc., +1-770-419-3355; or KatieBrazel of Fleishman Hillard, +1-404-739-0150, for CryoLife, Inc.

Web site: http://www.cryolife.com/